Moderna Shares Nearly Double as Melanoma Vaccine Clears Late-Stage Trial
Moderna and Merck shares surged after a phase 3 melanoma vaccine trial succeeded, as the US Treasury moved to calm bond markets, UK inflation rose on energy bills, and Unitree's stock market debut soared.
15 min read